PhRMA and our members are committed to bolstering pandemic preparedness and health care resiliency to make sure our country and American patients are stronger, healthier and better prepared for the next public health emergency. Having a robust pipeline of medicines to address AMR is a key part of that preparedness. If we fail to address this growing crisis, many modern medical advances that depend on antibiotics — such as routine surgery, cancer therapy and treatment of chronic disease — may be jeopardized.
Along with our government’s commitment to addressing the COVID-19 pandemic, we can be prepared for the next public health emergency if we all work together to ensure a sustainable pipeline for new antimicrobials for this crisis and those in years to come.
Download the fact sheet below, or learn more about antimicrobial resistance here.